您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Fluocinonide(Vanos)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Fluocinonide(Vanos)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Fluocinonide(Vanos)图片
CAS NO:356-12-7
规格:≥98%
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议
1g电议
2g电议
10g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)494.52
FormulaC26H32F2O7
CAS No.356-12-7
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 99 mg/mL (200.2 mM)
Water: <1 mg/mL
Ethanol: N/A
Other infoChemical Name: 2-((2S,6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-2,6b-difluoro-7-hydroxy-6a,8a,10,10-tetramethyl-4-oxo-2,4,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl acetate
InChi Key: WJOHZNCJWYWUJD-IUGZLZTKSA-N
InChi Code: InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1
SMILES Code: CC(OCC([C@@]12[C@H](OC(C)(C)O2)C[C@@H]3[C@]1(C)C[C@H](O)[C@@]4(F)[C@H]3C[C@H](F)C5=CC(C=C[C@@]54C)=O)=O)=O
SynonymsLidex, Lyderm, Metosyn, Topsyn, Fluocinolide, Vanos, Lonide
实验参考方法
In Vitro

In vitro activity: Fluocinonide cream has a lower potential to produce atrophic changes of the skin than either clobetasol cream or clobetasol propionate foam. Fluocinonide (Vanos) is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders. Target: Glucocorticoid Receptor Fluocinonide is a potent glucocorticoid steroid used topically as an anti-inflammatory agent for the treatment of skin disorders such as eczema and seborrhoeic dermatitis. Fluocinonide ranks as a 'high-potency' topical corticosteroid. Minimal amounts should be used for a minimal length of time to avoid the occurrence of adverse effects. Fluocinonide should not be used if infection is present. Fluocinonide is used in veterinary medicine. It is a treatment for allergies in dogs. Natural systemic cortisol concentrations can be suppressed for weeks after one week of topical exposure.

In VivoFluocinonide causes prompt and sustains pituitary-adrenocortical suppression in healthy dogs. Fluocinonide results in significant reduction of plasma cortisol and iACTH concentrations by day 2 of treatment in healthy dog, and the lower concentrations continued to day 5. One week after the last application of Fluocinonide, plasma iACTH concentrations in the corticosteroid-treated dogs has returned to the range of values for the control dogs; however, pre- and post-ACTH cortisol concentrations remains suppressed in Fluocinonide treated dogs. Two weeks after the last treatment, the pre-ACTH plasma cortisol concentrations of corticosteroid-treated dogs returns to those of the control dogs, but the post-ACTH plasma cortisol concentrations remains suppressed.
Animal modelDogs
Formulation & Dosage
ReferencesJ Drugs Dermatol. 2008 Jan;7(1):28-32; J Drugs Dermatol. 2008 Jan;7(1):28-32.